These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 27220716)

  • 1. Pooled patient level data are better suited than study level data to investigate the link between dipeptidyl peptidase-4 inhibitors and the risk of heart failure in type 2 diabetes.
    Patel T; Tesfaldet B; Gandotra C;
    BMJ; 2016 May; 353():i2920. PubMed ID: 27220716
    [No Abstract]   [Full Text] [Related]  

  • 2. No increased heart failure risk is reported with DPP-4 inhibitors.
    Wise J
    BMJ; 2016 Apr; 353():i2363. PubMed ID: 27118534
    [No Abstract]   [Full Text] [Related]  

  • 3. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety of incretin based drug treatments for type 2 diabetes.
    Bolen SD; Maruthur NM
    BMJ; 2016 Feb; 352():i801. PubMed ID: 26888024
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk of heart failure with dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Kundu A; Sardar P; Ghosh S; Patel P; Chatterjee S; Meyer TE
    Int J Cardiol; 2016 Jun; 212():203-5. PubMed ID: 27043061
    [No Abstract]   [Full Text] [Related]  

  • 6. Heart failure and dipeptidyl peptidase-4 inhibitors.
    Krum H; Skiba M; Wu S; Hopper I
    Eur J Heart Fail; 2014 Jun; 16(6):603-7. PubMed ID: 24687300
    [No Abstract]   [Full Text] [Related]  

  • 7. Inclusion of the EXAMINE study in a meta-analysis of the addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia.
    Boucaud-Maitre D
    BMJ; 2016 Jun; 353():i3186. PubMed ID: 27267596
    [No Abstract]   [Full Text] [Related]  

  • 8. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E; Cigolini M
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erroneous event count in a meta-analysis (dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus).
    Buisson M; Cornu C; Nony P
    Am J Cardiol; 2015 Mar; 115(6):852. PubMed ID: 25554535
    [No Abstract]   [Full Text] [Related]  

  • 10. Authors' reply to Tufan and colleagues and Boucaud-Maitre.
    Salvo F; Moore N; Arnaud M; Robinson P; Raschi E; De Ponti F; Bégaud B; Pariente A
    BMJ; 2016 Jun; 353():i3188. PubMed ID: 27267359
    [No Abstract]   [Full Text] [Related]  

  • 11. [DPP4 inhibitors: what is the cardiovascular risk?].
    Langrand C; Moulin P
    Rev Prat; 2015 Oct; 65(8):1039-41. PubMed ID: 26749701
    [No Abstract]   [Full Text] [Related]  

  • 12. Corrections needed to 2016 ESC and AHA guidelines on heart failure.
    Rydén L; Van de Werf F; Armstrong PW; McGuire DK; Standl E; Peterson ED; Holman RR
    Lancet Diabetes Endocrinol; 2017 May; 5(5):325-326. PubMed ID: 28395875
    [No Abstract]   [Full Text] [Related]  

  • 13. Do Dipeptidyl Peptidase-4 Inhibitors Increase the Risk of Heart Failure in Patients with Type 2 Diabetes?
    Hassanabad MF; Hassanabad AF; Fatehi M
    Curr Diabetes Rev; 2022; 18(8):e161221199093. PubMed ID: 34915838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saxagliptin, alone or in combination. No fewer complications; more cases of heart failure?
    Prescrire Int; 2014 Sep; 23(152):207. PubMed ID: 25325118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In process].
    Ecker-Schlipf B
    Med Monatsschr Pharm; 2016 Oct; 39(10):448-9. PubMed ID: 29979547
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.
    Scheen AJ
    Expert Opin Drug Saf; 2015 Apr; 14(4):505-24. PubMed ID: 25630605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl peptidase-iV inhibitors: fixing type 2 diabetes?
    McIntyre HF; Grant P
    Br J Hosp Med (Lond); 2007 Nov; 68(11):599-602. PubMed ID: 18087847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent safety updates on type 2 diabetes medications: a case report and the evidence for choosing among several available drugs for this patient.
    Sisson EM; Mills J; Chin L
    Am J Nurs; 2012 Dec; 112(12):49-53. PubMed ID: 23190674
    [No Abstract]   [Full Text] [Related]  

  • 19. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus.
    Patil HR; Al Badarin FJ; Al Shami HA; Bhatti SK; Lavie CJ; Bell DS; O'Keefe JH
    Am J Cardiol; 2012 Sep; 110(6):826-33. PubMed ID: 22703861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials.
    Kappel BA; Marx N; Federici M
    Nutr Metab Cardiovasc Dis; 2015 Aug; 25(8):697-705. PubMed ID: 26164634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.